Patents by Inventor Philip Spencer Rudland

Philip Spencer Rudland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treating cancer
    Patent number: 7989176
    Abstract: Provided is a method for screening for effective agents for the treatment of cancer which method comprises selecting a putative agent that is likely to disrupt a function mediated by a critical normal gene product, which function is required for the successful division and continued cell survival of cancer cells, and which function is not required for the successful division and continued cell survival of control cells, treating a cancer cell sample and a control cell sample with a purative agent and determining the cytotoxic effect of, and/or the growth inhibitory effect of the putative agent on these samples, and identifying an effective agent as an agent which is more cytotoxic to, and/or more inhibiting to the growth of the cancer cell sample than the control cell sample. This invention further provides an effective agent identified by this screening method and a method of treating a cancer patient with such an agent.
    Type: Grant
    Filed: March 25, 2003
    Date of Patent: August 2, 2011
    Assignee: Theryte Ltd.
    Inventors: Hilmar Meek Warenius, Philip Spencer Rudland, Laurence Anthony Seabra
  • Conditionally immortalized cell lines derived from transgenic animals
    Patent number: 6825394
    Abstract: The invention relates to mammalian cell lines and transgenic mammals. More particularly, it relates to a method for producing a rat cell line, a method for producing a transgenic rat, a transgenic rat, a rat cell line, cells and tissue obtained therefrom and uses therefore. The cell line derived from a transgenic mammal comprises: (i) a conditional oncogene, transforming gene or immortalising gene or a cell cycle affecting gene; and (ii) a cell type specific promoter. They include a neuronal cell line in which the cell type specific promoter is an NF-L gene promoter, and a mammary cell line in which the cell type specific promoter is a MMTV gene promoter. The conditional oncogene, transforming gene or immortalising gene is preferably a SV40tsA58 gene.
    Type: Grant
    Filed: October 16, 1998
    Date of Patent: November 30, 2004
    Inventors: Philip Spencer Rudland, Barry Roger Barraclough, Iain Charles Kilty, Barry Robert Davies, Guenter Schmidt
  • Prognostic indicator
    Publication number: 20040072189
    Abstract: A prognostic indicator for metastasis comprises an antibody directed against ostepontin.
    Type: Application
    Filed: September 12, 2003
    Publication date: April 15, 2004
    Inventors: Arthur John Smith, Philip Spencer Rudland
  • Treating cancer
    Publication number: 20030207792
    Abstract: Provided is a method for screening for effective agents for the treatment of cancer which method comprises testing a putative agent that is likely to disrupt a critical normal gene product present in said cancer for its cytotoxic and/or growth inhibitory effect upon a cancer cell sample, and identifying an effective agents as an agent which is cytotoxic to, and/or inhibiting to the growth of the cancer cell sample. This invention further provides an agent capable of disrupting a critical normal gene in such a manner as to be cytotoxic to, or inhibiting to the growth of a cancer cell, and a method of treating a cancer patient with such an agent.
    Type: Application
    Filed: October 17, 2002
    Publication date: November 6, 2003
    Inventors: Hilmar Meek Warenius, Philip Spencer Rudland, Laurence Anthony Seabra